0001 GMT - Integral Diagnostics gets a new bull at Bell Potter in anticipation of the enhanced scale offered by the imaging provider's merger with Capitol Health. Analyst Martyn Jacobs tells clients in a note that the combined Integral-Capitol business will become Australia's third-largest imaging provider, creating operating leverage and opportunities in telehealth. He says that regulatory changes could allow the group to extend operating hours, generating an additional A$11 million in fiscal 2026 revenue. Bell Potter initiates coverage with a buy rating and A$3.87 target price on the stock, which is up 4.0% at A$3.16. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 04, 2024 19:01 ET (00:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。